Modafinil Heumann (Modafinil)

• Modafinil is a wakefulness‑promoting agent used to treat sleep‑related disorders.
• Narcolepsy: reduces excessive daytime sleepiness and improves alertness in patients with narcolepsy.
• Obstructive sleep apnea‑related excessive daytime sleepiness: alleviates residual sleepiness in patients with OSA who are using optimal therapy.
• Shift work sleep disorder: helps maintain wakefulness in individuals whose work schedule conflicts with normal circadian rhythms.

• Modafinil acts primarily by inhibiting the reuptake of dopamine, leading to increased extracellular dopamine concentrations in brain regions that regulate wakefulness. It also influences orexinergic, histaminergic, and noradrenergic pathways, enhancing neuronal activity that promotes alertness without directly stimulating adrenergic receptors. Additionally, modest effects on glutamate release may contribute to its cognitive‑enhancing profile.

Modafinil may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often reported during treatment.
• Nausea: transient stomach upset that may resolve with continued use.
• Insomnia: difficulty falling or staying asleep, especially if taken later in the day.
• Anxiety: feelings of nervousness or tension.
• Dry mouth: reduced salivation causing oral discomfort.
• Dizziness: light‑headed sensation, usually temporary.

Serious or Rare Side Effects

• Severe rash or Stevens‑Johnson syndrome: skin reactions requiring immediate medical attention.
• Psychiatric symptoms: emergence of hallucinations, mania, or depression.
• Cardiovascular events: chest pain, hypertension, or arrhythmias.
• Hypersensitivity reactions: swelling, difficulty breathing, or anaphylaxis.
• Liver enzyme elevation: abnormal hepatic function tests.

When prescribing Modafinil, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular assessment: evaluate blood pressure and heart disease before initiating therapy.
• Psychiatric history: screen for prior psychosis, mania, or severe depression.
• Concomitant medications: review use of CYP3A4 inducers or inhibitors that may alter drug levels.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Driving and machinery: advise patients to assess personal response before operating vehicles or heavy equipment.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight, and store below 25 °C.

Modafinil can affect the plasma concentrations of several co‑administered drugs, requiring attention to potential significant interactions.

Major Interactions (Avoid)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce Modafinil exposure.
• CYP2C19 inhibitors (e.g., fluvoxamine): can increase Modafinil levels and risk of adverse effects.
• Antiepileptic drugs (e.g., phenytoin): may reduce Modafinil levels.

Moderate Interactions (Monitor Closely)

• Hormonal contraceptives: Modafinil may decrease efficacy, requiring alternative or backup methods.
• Anticoagulants (e.g., warfarin): possible alteration of INR, necessitating closer monitoring.
• Antidepressants (e.g., SSRIs): may increase risk of serotonin syndrome, monitor for symptoms.
• CNS depressants (e.g., benzodiazepines): may enhance sedative effects, monitor drowsiness.